Segetis Inc

www.segetis.com

Segetis is a technology-enabled green chemistry company producing versatile chemical buildi

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

Cell and Gene Therapy, Industrial Impact

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

news image

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More

MedTech, Industrial Impact

SOPHIA GENETICS AND QIAGEN PARTNER TO BOOST NEXT-GEN SEQUENCING

SOPHiA GENETICS and QIAGEN | March 06, 2023

news image

SOPHiA GENETICS, a healthcare cloud-based software company, announced a new partnership with QIAGEN N.V. that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to improve tumor analysis via next-generation sequencing (NGS). Customers can utilize QIAseq panels with SOPHiA DDM™, a cloud-based data analysis platform to enable new research perspectives. The partnership will support the detection of somatic variants using QIAseq targeted DNA pro panels for...

Read More
news image

Cell and Gene Therapy

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More
news image

Cell and Gene Therapy, Industrial Impact

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More
news image

MedTech, Industrial Impact

SOPHIA GENETICS AND QIAGEN PARTNER TO BOOST NEXT-GEN SEQUENCING

SOPHiA GENETICS and QIAGEN | March 06, 2023

SOPHiA GENETICS, a healthcare cloud-based software company, announced a new partnership with QIAGEN N.V. that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to improve tumor analysis via next-generation sequencing (NGS). Customers can utilize QIAseq panels with SOPHiA DDM™, a cloud-based data analysis platform to enable new research perspectives. The partnership will support the detection of somatic variants using QIAseq targeted DNA pro panels for...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us